Dr. Behl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2800 L St
Suite 300
Sacramento, CA 95816Phone+1 916-453-3300
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2006 - 2009- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2003 - 2006
Christian Medical College LudhianaClass of 1996
Certifications & Licensure
CA State Medical License 2009 - 2025
MN State Medical License 2006 - 2010- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) Start of enrollment: 2019 Jul 26
- Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Start of enrollment: 2020 Aug 13
- Ashwagandha for Cognitive Dysfunction Start of enrollment: 2023 Jan 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 194 citationsPhase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma...Ramesh K. Ramanathan, Shannon McDonough, Philip A. Philip, Sunil R. Hingorani, Jill Lacy
Journal of Clinical Oncology. 2019-02-28 - 94 citationsAbsolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia.D. Behl, Luis F. Porrata, Svetomir N. Markovic, Louis Letendre, R. K. Pruthi
Leukemia. 2006-01-01 - 6 citationsPertuzumab Plus Trastuzumab in Patients With Lung Cancer WithMutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.Apar K Ganti, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Elie G Dib
JCO Precision Oncology. 2023-06-01
Press Mentions
The Cancer Treatment Within YouNovember 20th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
